These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1346763)

  • 1. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.
    Gullick WJ; Bottomley AC; Lofts FJ; Doak DG; Mulvey D; Newman R; Crumpton MJ; Sternberg MJ; Campbell ID
    EMBO J; 1992 Jan; 11(1):43-8. PubMed ID: 1346763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers.
    Sharpe S; Barber KR; Grant CW
    Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
    Guy PM; Carraway KL; Cerione RA
    J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of proto-oncogenic and mutant forms of the transmembrane region of the Neu receptor in TFE.
    Houliston RS; Hodges RS; Sharom FJ; Davis JH
    FEBS Lett; 2003 Jan; 535(1-3):39-43. PubMed ID: 12560075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformation of the transmembrane domain of the epidermal growth factor receptor.
    Brandt-Rauf PW; Monaco R; Pincus MR
    J Protein Chem; 1994 Feb; 13(2):227-31. PubMed ID: 7914727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
    Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
    J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.
    Brandt-Rauf PW; Pincus MR; Chen JM
    J Protein Chem; 1989 Dec; 8(6):749-56. PubMed ID: 2576207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor.
    Smith SO; Smith CS; Bormann BJ
    Nat Struct Biol; 1996 Mar; 3(3):252-8. PubMed ID: 8605627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmembrane interactions in the activation of the Neu receptor tyrosine kinase.
    Smith SO; Smith C; Shekar S; Peersen O; Ziliox M; Aimoto S
    Biochemistry; 2002 Jul; 41(30):9321-32. PubMed ID: 12135353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure prediction of the dimeric neu/ErbB-2 transmembrane domain from multi-nanosecond molecular dynamics simulations.
    Sajot N; Genest M
    Eur Biophys J; 2000; 28(8):648-62. PubMed ID: 10663532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence-dependent oligomerization of the Neu transmembrane domain suggests inhibition of "conformational switching" by an oncogenic mutant.
    Beevers AJ; Damianoglou A; Oates J; Rodger A; Dixon AM
    Biochemistry; 2010 Apr; 49(13):2811-20. PubMed ID: 20180588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmembrane peptides from tyrosine kinase receptor. Mutation-related behavior in a lipid bilayer investigated by molecular dynamics simulations.
    Samna Soumana O; Aller P; Garnier N; Genest M
    J Biomol Struct Dyn; 2005 Aug; 23(1):91-100. PubMed ID: 15918680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence-related behaviour of transmembrane domains from class I receptor tyrosine kinases.
    Jones DH; Barber KR; Grant CW
    Biochim Biophys Acta; 1998 May; 1371(2):199-212. PubMed ID: 9630629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of a tendency to self-association of the transmembrane domain of ErbB-2 in fluid phospholipid bilayers.
    Sharpe S; Barber KR; Grant CW
    Biochemistry; 2002 Feb; 41(7):2341-52. PubMed ID: 11841227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural implications of a Val-->Glu mutation in transmembrane peptides from the EGF receptor.
    Sharpe S; Grant CW; Barber KR; Giusti J; Morrow MR
    Biophys J; 2001 Dec; 81(6):3231-9. PubMed ID: 11720988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
    Lofts FJ; Hurst HC; Sternberg MJ; Gullick WJ
    Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
    Sajot N; Genest M
    J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
    Brandt-Rauf PW; Rackovsky S; Pincus MR
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence dependence of BNIP3 transmembrane domain dimerization implicates side-chain hydrogen bonding and a tandem GxxxG motif in specific helix-helix interactions.
    Sulistijo ES; MacKenzie KR
    J Mol Biol; 2006 Dec; 364(5):974-90. PubMed ID: 17049556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors.
    Ben-Baruch N; Yarden Y
    Proc Soc Exp Biol Med; 1994 Jul; 206(3):221-7. PubMed ID: 7912439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.